Helping you access rare reality

HRW RareFocus combines specialist rare disease expertise and recruitment, tailored methodologies and thoughtful analysis to help navigate complexity, uncover deeper insight and translate understanding into action.

Rare diseases demand a different approach.

Rare disease market research is about elevating voices that are often underrepresented, then translating complex lived and clinical experiences into clear decisions for strategy, launch planning and communications.

The challenge is not simply recruitment. It is knowing who to include, how to engage them sensitively, how to maximise every interaction and how to interpret insight when sample sizes are smaller and experiences are highly varied.

This matters because rare disease brands often operate in environments with limited precedent, evolving treatment pathways and high-stakes decision making. Success depends on understanding the full ecosystem surrounding the patient, reaching communities that are often difficult to access, and translating limited but meaningful evidence into actionable insights.

Union

Our Approach

The work of our specialist rare disease team, HRW RareFocus, is underpinned by integrated working with HRW’s expert Market Research teams in quant and qual, Behavioural Science, Data Science, and Patient Research. Our approach is built around three connected principles:

Disease focus

We adapt every design to the specific condition, recognising that each rare disease has its own variability, diagnostic pathway, treatment context and patient reality.

Ecosystem focus

We look beyond the patient alone, incorporating HCPs, caregivers, patient associations, KOLs, payers and healthcare system context where relevant.

Design focus

We design thoughtful, flexible research that reduces respondent burden, maximises engagement and extracts richer insight from every conversation.

Research design across the product lifecycle

Flexible methodologies designed with hard-to-reach populations in mind

-Behavioural science through HRW Shift, identifying biases, heuristics and behavioural drivers to help understand what is influencing stakeholders across the ecosystem
-Advanced analytics and data science support for smaller and more complex datasets
-Insight activation through HRW Studio, including journey maps, infographics, videos, immersion tools and stakeholder workshops

Ultimately helping you move beyond what people say to understand how rare diseases are experienced in the real world.

HRW RareFocus combines rare disease specialism with the breadth of HRW’s centres of excellence, enabling clients to get closer to rare disease reality and make decisions with greater confidence.

Design for the specific disease, not the category label
With experience across 40+ rare diseases, we use cross-therapy-area pattern recognition while still tailoring each project to the unique condition, context and stakeholder mix.
Build a complete ecosystem view
Rare disease insight often depends on triangulation across multiple stakeholder types.
Recruit with precision and sensitivity
We use multichannel recruitment strategies, specialist partners, patient association routes, referrals and online channels where appropriate, adapting continuously during fieldwork.
Maximise insight quality when scale is limited
Every conversation matters. We use flexible, engaging methods and expert moderation to uncover nuance without overburdening respondents.
Add behavioural explanation, not just description
HRW Shift identifies the biases and behavioural drivers that can shape diagnosis, treatment choice, communication response and adoption.
Create outputs that live beyond the debrief
Through multimedia, storytelling, workshops and immersive deliverables, we help teams internalise rare disease realities and act on the research.

Case-studies

  • Patient journey and differentiation in a rare genetic heart disease

    The Challenge

    In preparation for the launch of our client’s treatment within oHCM, there was a need to grow understanding of the oHCM treatment landscape and awareness, usage and perceptions of the first-in-class CMI.

    To ensure the launch was competitive, there was also a need to find factors that differentiated our client’s product from other CMIs to feed into positioning and communication strategies and establish their treatment as a go-to in oHCM.

    Our Solution
    • A qualitative deep-dive in EU5 markets to test the product’s TPP and understand how the treatment could be strategically positioned to encourage adoption and rapid market share increase
    • A follow-up quantitative phase to provide quantified support for qualitative findings, alongside key metrics like market share, treatment decision making and drivers or barriers to CMI adoption
    • Behavioural science analysis to uncover hidden biases that drive treatment decision-making, including barriers to switching for HCPs using existing CMIs or to onboarding for CMI-naïve HCPs
    Outcome
    • A detailed understanding of how the client’s product can stand out in the oHCM market, including which clinical data differentiates most from other CMIs, how endpoints should be expressed, and which endpoints are most likely to encourage long-term use.
    • A robust understanding of the patient journey, from diagnosis to ongoing management, including which specialists are involved and the roles of different centres. Statistical analysis from our data science team helped to understand current and predicted market share.
    • Actionable, evidence-based recommendations from HRW Shift that outlined identified biases (e.g., the Halo effect) which create treatment inertia and could impact initial uptake of our client’s treatment, with recommendations of how to overcome these and, in some cases, utilise them for success.
  • Ongoing annual ATU in rare disease to measure performance and inform future strategy

    The Challenge

    The client’s novel product in an orphan disease was launched in a competitive and evolving treatment landscape. Insights were needed to support strategic planning as well as inform tactical focus areas, with objectives including:

    • Key drivers influencing treatment choice, including local variations
    • Treatment perceptions across the class of therapy, along with barriers to use
    • Country‑specific nuances to equip local teams with the insights needed to take informed targeted action
    • Embedding a tracker moved from another provider, evolving it to meet current client needs while carefully preserving priority KPIs from previous waves
    Our Solution

    The research approach was structured to ensure recruitment of the right respondents and to support the collection of robust and reliable data:

    • 25-minute survey to collect data across EU4 and ex-EU4 markets, capturing metrics such as brand awareness, usage and anticipated changes in future prescribing
    • Inclusion of appropriate HCP cohorts (i.e., active treaters and referrers), incorporating the client’s target centres
    • Integration of behavioural science: at materials design to influence questionnaire design, and across insights analysis and interpretation to assess product capabilities and identify motivational drivers of adoption with potential to leverage
    Outcome
    • Clear picture of market dynamics, highlighting areas of further opportunity for the brand
    • Analysis of prescribing factors revealed hidden drivers of class choice that will be leveraged by brand teams to refine tactical messaging
    • Revealed opportunities beyond promotional messaging, e.g., targeted HCP education to encourage disease management reflection and behaviour change
    • Identification of appropriate patient sub-groups where the product may be further leveraged to increase market share
    • Behavioural insights highlighted key underlying psychological capabilities, motivations, and opportunities in this therapy area that the client can address to influence physician behaviours

HRW RareFocus Team

Img

Jess Woodhead

Senior Vice President - Manhattan
A passion for elevating the voice of the patient including specific interest in rare immunology, dermatology and endocrine conditions.
See Profile

Jess Woodhead

Senior Vice President - Manhattan
shorthand
Img

Yasmeen Elsakary

Research Manager - Manhattan
Experience spanning congenital and oncologic rare diseases, with a strong interest in amplifying patient, HCP, and caregiver perspectives.
See Profile

Yasmeen Elsakary

Research Manager - Manhattan
shorthand
Img

Rachel Schooler

Research Manager - Manhattan
Longstanding commitment to paediatric rare disease, with a particular interest in caregiver experiences and diagnostic pathways.
See Profile

Rachel Schooler

Research Manager - Manhattan
shorthand
Img

Faye Holmes

Research Director - London
Expertise spanning rare haematology, respiratory and sleep disorders, with a focus on uncovering the needs and experiences of all involved.
See Profile

Faye Holmes

Research Director - London
shorthand
Img

Isabella Sheridan

Research Manager - London
Combining expertise across neurological and metabolic rare diseases to uncover patterns shaping patient journeys across global healthcare systems.
See Profile

Isabella Sheridan

Research Manager - London
shorthand
Img

Amy Russell

Associate Director, Field - London
Extensive knowledge of conducting successful fieldwork in the rare disease universe. For both HCPs, patients and CGs, particularly within the quant space.
See Profile

Amy Russell

Associate Director, Field - London
shorthand
Img

Blaine Siegel

Project Manager, Field - Manhattan
Committed to recruiting individuals living with rare diseases, while providing a platform for both patients and the providers who support them.
See Profile

Blaine Siegel

Project Manager, Field - Manhattan
shorthand

Contacts Us




    checkedI would like to receive news and information from HRW
    checkedI agree to the HRW privacy policy